Barriers to successful dichoptic treatment for amblyopia in young children.
Amblyopia
Barriers to successful treatment
Dichoptic treatment
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
28
09
2020
accepted:
07
04
2021
revised:
13
03
2021
pubmed:
1
6
2021
medline:
1
10
2021
entrez:
31
5
2021
Statut:
ppublish
Résumé
In an ongoing randomised clinical trial comparing dichoptic VR video games with patching for amblyopia, we evaluated any potential barriers to successful use of this novel amblyopia treatment method. From December 2017, all newly diagnosed amblyopic children were recruited. Excluded were children under age 4 and patients with strabismus exceeding 30PD. The video game was played for 1 h per week at the outpatient clinic under direct supervision. Records were kept of difficulties encountered during treatment and categorised into domains. Factors influencing the successful completion of this treatment were identified and related to patient characteristics. Ninety-one children were recruited for the trial, 20 parents refused participation before randomisation, because of the logistical challenges the outpatient dichoptic treatment would cause them. Of the 17 children who commenced dichoptic treatment (median age 6.2 years; IQR 4.9-8.4 years), 10 did not complete treatment. Children under age 5.5 years were unable to comprehend the game settings or the game itself. Older children (N = 7; 41%) were less willing to comply with the video game. Loss of interest in the game (N = 8; 47%) was found to be a limiting factor at all ages. Half of the children failed to complete VR dichoptic treatment, mainly due to young age. In countries with nationwide screening where amblyopia is detected before age 6, the applicability of such dichoptic treatment is limited.
Identifiants
pubmed: 34057550
doi: 10.1007/s00417-021-05193-1
pii: 10.1007/s00417-021-05193-1
pmc: PMC8478762
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
3149-3157Informations de copyright
© 2021. The Author(s).
Références
JAMA Ophthalmol. 2016 Dec 1;134(12):1391-1400
pubmed: 27812703
Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4393-400
pubmed: 17003431
Vision Res. 2018 Jul;148:1-14
pubmed: 29709618
Proc Natl Acad Sci U S A. 2011 Jun 21;108(25):10081-6
pubmed: 21670271
Vision Res. 2014 Oct;103:11-9
pubmed: 25130409
Invest Ophthalmol Vis Sci. 2004 Sep;45(9):3048-54
pubmed: 15326120
Invest Ophthalmol Vis Sci. 2015 Jun;56(6):4061-75
pubmed: 26114483
Ophthalmology. 2019 Mar;126(3):456-466
pubmed: 30352226
Vision Res. 2015 Sep;114:17-30
pubmed: 25637854
J AAPOS. 2015 Feb;19(1):6-11
pubmed: 25727578
Ophthalmology. 2020 Feb;127(2):261-272
pubmed: 31619356
Sci Rep. 2015 Feb 26;5:8482
pubmed: 25719537
Vision Res. 2015 Sep;114:4-16
pubmed: 25906685
Am J Ophthalmol. 2018 Feb;186:104-115
pubmed: 29196184
Vision Res. 2015 Sep;114:173-87
pubmed: 25917239
JAMA Ophthalmol. 2016 Dec 1;134(12):1402-1408
pubmed: 27832248
J AAPOS. 2019 Jun;23(3):160.e1-160.e5
pubmed: 31103562
Ophthalmic Physiol Opt. 2014 Mar;34(2):146-62
pubmed: 24588532
Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3476-84
pubmed: 20089868
Vision Res. 2015 Sep;114:161-72
pubmed: 25676883
Vision Res. 2020 Nov;176:118-129
pubmed: 32866759
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):E733-41
pubmed: 21896742